ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET
Company Participants
Joe Burnett – Chief Executive Officer
Danilo D’Alessandro – Chief Financial Officer
Conference Call Participants
Frank Takkinen – Lake Street Capital Markets
William Wood – B. Riley Securities
Operator
Greetings, and welcome to the ClearPoint Neuro, Inc. First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
Comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, statements related to anticipated industry trends, the company’s plans, prospects and strategies, both preliminary and projected, the size of total addressable market or the market opportunity for the company’s products and services and management’s expectations, beliefs, estimates or projections regarding future revenue, results of operations or the adequacy of cash and cash equivalent balances to support operations and meet future obligations. Actual results or trends could differ materially. The company undertakes no obligation to revise forward-looking statements for new information or future events.
For more information, please refer to the company’s annual report on Form 10-K for the year ended December 31, 2023, which has been filed with the Securities and Exchange Commission, and the company’s quarterly report on Form 10-Q for the three months ended March 31, 2024, which the company intends to file within the Securities and Exchange Commission on or before May 15, 2024. All the company’s filings may be obtained from the SEC or the company’s website at www.clearpointneuro.com.
It is now my pleasure to introduce your host, Joe Burnett, Chief Executive Officer. Thank you, Joe. You may begin.
Joe Burnett
Thank you and thank you to all of the investors and analysts on today’s call for being a part of the ClearPoint vision and journey. Our mission and our priority is to help restore quality of life to patients and their families who are suffering from some of the most debilitating neurological disorders imaginable.
In the first quarter of 2024, we have continued to make progress across our four-pillar growth strategy, including biologics and drug delivery, functional neurosurgery navigation, therapy and access products and in achieving global scale. In 2024, we expect meaningful contributions from not just one, but from all four of these growth pillars as we launch new products and services throughout the year. These new products will allow us to expand into the operating room, expand into laser therapy, expand internationally, and expand into more comprehensive preclinical and clinical trial services as many of our biologics and drug delivery partner’s progress through the regulatory process and begin first-in-human clinical trials for their therapy.